Bicara Therapeutics Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Bicara Therapeutics Inc. (BCAX) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 8.33 million shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-03-30
- Bicara Therapeutics Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 8.33M shares, a 7.56% increase from fiscal 2024.
- Bicara Therapeutics Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 7.75M shares.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|
| 2025-12-31 | 8.33M shares 10-K · filed 2026-03-30 |
| 2024-12-31 | 7.75M shares 10-K · filed 2026-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B |